Abstract Details

Title Readmission In Acute Ischemic Stroke Patients Undergoing Endovascular Treatment

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S6 - Cerebrovascular Disease and Interventional Neurology: Acute Stroke Treatment (4:40 PM-4:48 PM)

Poster/Presentation
Number 005

Background

Recent trials have demonstrated a reduction in death or disability with endovascular treatment in patients with acute ischemic strokes. However, readmission rates and predictors are not known.

Objective

To identify rates and factors associated with 30-day readmission after endovascular treatment in ischemic stroke patients.

Design/Methods

Nationwide Readmissions Data (NRD) between 2010 and 2017 was utilized to identify endovascular treatment in acute ischemic stroke patients using ICD-9 and ICD-10 codes. We used hierarchical logistic regression model to identify factors associated with 30-day readmissions.

Results

Results: Among 17, 562 acute ischemic stroke patients who survived to discharge after endovascular treatment, 2334 (13.29%) were readmitted within 30-days. Age => 65 years (odds ratio [OR]: 1.23, 95% confidence interval [CI]: 1.09 to 1.39, p =0.0005), chronic kidney disease (OR: 1.28, 95%CI: 1.12 to 1.47, p = 0.0004), congestive heart failure (OR: 1.25, 95%CI: 1.13 to 1.39, p <.0001), post procedure intracranial hemorrhage (OR: 1.09, 95%CI: 0.99 to 1.20, p = 0.04) and diabetes mellitus (OR: 1.09, 95%CI: 0.99 to 1.20, p = .09) during the index hospitalization were associated with readmission within 30 days.

Conclusions

In this large nationally representative study, nearly one in 10 patients were readmitted within 30 days after discharge in acute ischemic stroke patients undergoing endovascular treatment. Medical comorbidities and post procedure intracranial hemorrhage were associated with 30-day readmission.

Authors/Disclosures
Saqib A. Chaudhry, MD PRESENTER	Dr. Chaudhry has nothing to disclose.
Ibrahim Laleka	No disclosure on file
Hussan Gill	Mr. Gill has nothing to disclose.
Mohammad Rauf A. Chaudhry, MD, MBBS (University of Texas at Houston)	Dr. Chaudhry has nothing to disclose.
Ameer Hassan, DO (Valley Baptist Medical Center)	Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Stryker. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Penumbra. Dr. Hassan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerenovus. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Viz.ai. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Hassan has received research support from GE Healthcare.
Haseeb A. Rahman, MD (Houston Methodist)	Dr. Rahman has nothing to disclose.
	No disclosure on file
	No disclosure on file
Sairah Bashir, MD	Dr. Bashir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic .
	No disclosure on file
Yun Fang	No disclosure on file
Laith Altaweel, MD (Inova)	No disclosure on file
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.